Hikma Pharmaceuticals, a major multinational pharmaceutical group with operations across Mena, Europe and the US, reported a 16 per cent increase in Group revenue to $738 million during first six months of the year.

The increase in revenue was driven by the strong performance of the injectables business, explained Said Darwazah, chief executive officer of Hikma.

A total of 49 products were launched and 140 product approvals were received in the first half of 2014.

“I am very pleased with our first half results, which reflect strong underlying performance in our businesses and our success in capturing a number of specific market opportunities,” Darwazah said.

“In the Mena region, our focus on new, higher value products is delivering strong results in key markets.  Our injectables business delivered an excellent performance, as we captured a number of attractive market opportunities. I am delighted we have acquired the Bedford assets, which will add products, R&D capabilities and capacity to support future growth for the global injectables business.

“Our generics business is performing extremely well and we are working hard to strengthen the product portfolio and pipeline. Overall, the Group is benefiting from our diversified business model and I am pleased to be reiterating our Group continued revenue growth for the full year,” he added. - TradeArabia News Service